Ibio, Inc. · NASDAQ:IBIO
Ibio — Noble Financial Sixth Annual Equity Conference ONTRACK 2010
25 slides from Ibio's conference presentation, Jun 4, 2010
Slide 1: Game-Changing Technology for the Vaccine and Therapeutic Biologics Business
Exhibit 99.1 Game-Changing Technology for the Vaccine and Therapeutic Biologics Business Noble Financial Sixth Annual Equity Conference ONTRACK 2010
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and which may
Slide 3: iBioLaunch Platform: Best Technology for New Influenza Vaccines
iBioLaunch Platform: Best Technology for New Influenza Vaccines Best: iBioLaunch Technology Rapid Production Cycles Low Capital and COGs Surge Capacity Photo from Novartis Photo from Medicinenet.com No Animal/Human Pathogens Newer: Animal Cell Technology Traditional: Egg Technology Expensive Facilit
Slide 4: How Will iBio Create Shareholder Value?
How Will iBio Create Shareholder Value? High-Reward / Low-Risk Business Strategy Broadly-sourced license revenue from defined product categories and geographic regions – corporations & governments Value-enhancing early-stage development and co-development of products Based on Disruptive iBioLaunch™
Slide 5: A Substantial Business Opportunity: Address International Needs for a Flexible and Efficient Vaccine and Protein Manufacturing Platform
A Substantial Business Opportunity: Address International Needs for a Flexible and Efficient Vaccine and Protein Manufacturing Platform “Some analysts state that the “For generations, the United States has neglected to nurture availability of more expensive, the technologies and systems needed to re
Slide 6: iBio's Proprietary Technology Enables Flexible and Efficient Bio-Product Manufacturing
iBio’s Proprietary Technology Enables Flexible and Efficient Bio-Product Manufacturing iBio Opportunities: Vaccines and Bio-defense Corporations seek entry into lucrative vaccine markets Nations seek regional autonomy for response to outbreaks and/or bio-defense iBio Opportunities: Therapeutic Prote
Slide 7: Problem: Nations Are Poorly Prepared for Pandemics
Problem: Nations Are Poorly Prepared for Pandemics “Pandemics are global but political calculation to confront them is decidedly local,” Yanzhong Huang, YaleGlobal – September 2009 Federal officials predicted that 160 million doses of H1N1 vaccine would be available by October. In reality, there wer
Slide 8: Problem: Bio-Terrorist Attacks Are Inevitable
Problem: Bio-Terrorist Attacks Are Inevitable Washington Post – December 29, 2004 – “Only a thin wall of terrorist ignorance and inexperience now protects us.” -- Richard Danzig, former Navy Secretary and Pentagon bioterrorism consultant CNN – January 26, 2010 – “A commission set up to assess nation
Slide 9: The iBio Solution
The iBio Solution Deployment of the iBioLaunch™ Platform to Produce Vaccines for Pandemic Outbreaks and Combat Bioterrorism Dramatic Improvement in Speed of Response Days and weeks versus months Location Flexibility and Practical Surge Capacity Modular design and ease of tech transfer enable regiona
Slide 10: Third Party Investments in iBioLaunch Platform Vaccine Applications
Third Party Investments in iBioLaunch Platform Vaccine Applications The Bill & Melinda Gates Foundation and the Sabin Vaccine Institute - $ 33.3 million for iBioLaunch platform applications Avian Influenza Vaccine - $ 11.4 million Malaria Vaccine - $ 13.3 million Sleeping Sickness Vaccine - $ 8.2 mi
Slide 11: iBio Opportunities: Corporations Entering Vaccine Markets
iBio Opportunities: Corporations Entering Vaccine Markets & Nations Recognizing Pandemic Disease and Bioterrorism as National Security Threats 1. iBioLaunch technology superior for recombinant vaccines in comparison to bioreactor based systems No animal components or human pathogens Lower cost of go
Slide 12: The Market for New and Expanded Vaccine and Bio-defense Applications
The Market for New and Expanded Vaccine and Bio-defense Applications Global vaccine market projected at $32 billion in 2012 Influenza vaccine market projected > $4 billion in 2010 Bio-defense Vaccines U.S. spending for 2010 approximately $5 billion Tropical Diseases Gates Global Access Agreement Mal
Slide 13: iBio Opportunities: Corporations Developing Protein Therapeutics
iBio Opportunities: Corporations Developing Protein Therapeutics Orphan Medical Products iBioLaunch technology flexibility makes feasible addressing small population, high-value proteins Bio-similar and Bio-better Products iBioLaunch technology is applicable to all currently marketed biotech therape
Slide 14: The iBio Solution: Advantages for Therapeutic Protein Manufacturing
The iBio Solution Advantages of iBioLaunch™ Technology For Therapeutic Protein Manufacturing Best Economy of Production Reduced cost of materials, More efficient space utilization, Lower process costs, and Reduced amortization and depreciation expenses Facility Expansion Efficiency Time frame to bri
Slide 15: Achievements of iBioLaunch Technology in Therapeutic Protein Applications
Achievements of iBioLaunch Technology in Therapeutic Protein Applications: Efficient production of monoclonal antibodies, including proprietary product candidates for influenza and anthrax Proven applicable to interferons, growth factors, therapeutic enzymes, insulin, lectins, protease inhibitors, n
Slide 16: Market(s) for iBio Relevant Protein Therapeutics
Market(s) for iBio Relevant Protein Therapeutics Orphan Drug Opportunities Entry enhanced by 50% orphan drug development cost U.S. tax credit Novartis alone sells over $8 billion in orphan drugs 2,116 orphan drug designations approved by the FDA since 1983 Pfizer – Protalix deal validates big pharma
Slide 17: Intellectual Property
Intellectual Property Product Filings (U.S. and International) Influenza vaccines HPV vaccines Influenza monoclonal antibodies Anthrax vaccines Plague vaccine Trypanosomiasis and Malaria vaccines Technology Filings (U.S. and International) Virus-induced gene silencing in plants Activation of transge
Slide 18: Fraunhofer USA CMB – iBio Relationship
Fraunhofer USA CMB – iBio Relationship Fraunhofer USA CMB is a not-for-profit R&D organization Develops plant-based technologies to develop and manufacture vaccines and therapeutic biologics Specialists in vaccine development, plant molecular biology, immunology, and protein engineering Fraunhofer U
Slide 19: Synergy of iBio-CMB Collaboration Enhances Rate of Technical Innovation
Synergy of iBio-CMB Collaboration Enhances Rate of Technical Innovation Non-dilutive and highly accretive collaboration with Fraunhofer USA CMB Leveraged funding for technology / product development >$70 million through 2010 Dec. 2009 - $9.85 million from Bill & Melinda Gates Foundation for malaria;
Slide 20: iBioLaunch
iBioLaunch™ Accelerated High Capacity Production of Pharmaceutical Proteins Infiltrate with agrobacteria Design & Clone target gene containing launch synthesize into “launch vectors Harvest biomass & target gene vector” recover target protein Grow plants hydroponically Grow Target protein agrobacter
Slide 21: Management Team and Directors
Management Team and Directors Management Robert B. Kay - CEO & Executive Chairman Robert Erwin - President Frederick Larcombe, CPA – Interim CFO Vidadi Yusibov, Ph.D. - Chief Scientific Officer Board of Directors Robert B. Kay – Executive Chairman Dr. Pamela Bassett – Cantor Fitzgerald Glenn Chang –
Slide 22: iBio Valuation Metrics
iBio Valuation Metrics Industry Data Median Upfront Payments in Post-Phase 1 Clinical Development: $20 Million (27 deals - ReCap) Product Royalties: Preclinical 0 to 5%; Clinical 5 to 10%, Launched Products 8 to 20% Platform Royalties: Up to 11.7% Addressable Markets: Total Approximately $100 Billio
Slide 23: Recap: iBio's Value Proposition
Recap: iBio’s Value Proposition Diversified licensing approach to commercialize proprietary platform Less capital required vs. single-product biotech Non-dilutive financing enhances value Superior technology with third party validation in hand Large and growing markets Early and low-risk revenue Sto
Slide 24: Financial Metrics
Financial Metrics Cash and Equivalents: $1.5 million (as of 3/31/10) No Debt Stock Price: (OTCBB: IBPM) $1.02 on 5/28/10 Market-Cap: $28.8 Million Shares Outstanding: 28.3 million Float: 14.2 million
Slide 25: Contact
9 Innovation Way, Suite 100 Newark, DE 19711 www.ibioinc.com Contact: Investor Contact: Media Contact: Robert Erwin Jeffrey Benison Melody A. Carey President Managing Director Co-President iBio, Inc. Little Gem Life Science Partners Rx Communications Group 302-355-2335 212-334-8709 917-322-2571 rerw
iBio — Noble Financial Sixth Annual Equity Conference ONTRACK 2010 on 6ix